MAPS donated $15,046.25 to McLean Hospital, affiliated with Harvard Medical School. The donation is to enable Dr. John Halpern to develop a protocol for the use of MDMA-assisted psychotherapy in the treatment …
Letters in Science. An exchange of letters about MDMA dopaminergic neurotoxicity between the MAPS MDMA/PTSD team and the NIDA-funded research team of Ricaurte et al. appeared in the journal Science, June …
On May 28, 2003, José Carlos Bouso, PhD, learned that a Letter to the Editor that he wrote to the Spanish Medical Journal Medicina Clínica (Clinical Medicine), was accepted for publication. The …
Investigators: Manel Barbanoj, MD, PhD and Jordi Riba Institute de Recerca, Hospital de Sant Pau – Barcelona, Spain Sponsor: Institut de Reserca, Hospital de la Santa Creu i Sant Pau (HSCSP) The …
Investigator: Evgeny Krupitsky, MD, PhD St. Petersburg, Russia Contact Sponsor: MAPS, Heffter Clinical study, drug administration phase completed, 70 patients treated (35 in the experimental and 35 in …
MAPS, MPP and Dr. Ethan Russo filed an updated version of this amicus curiae brief in the US Court of Appeals for the Ninth Circuit case of Angel Raich et al. v. John Ashcroft as Attorney General and Asa …
Investigators: Juan Sanchez-Ramos, MD, PhD and Deborah Mash, PhD Unversity of Miami Medical School – Florida, USA Sponsor: University of Miami, MAPS Clinical study Phase I begun (up to 2 mg/kg), …
On April 28, 2003, a lengthy article in the prominent Spanish magazine Interviu reported on the controversy surrounding the Spanish MDMA/PTSD study and brought to light the fact that the Madrid Anti-Drug …
April 25, 2003. MAPS publishes "DEA and the UMass Amherst Medical Marijuana Production Facility: An Update" by Rick Doblin, Ph.D. (pdf format) in the MAPS Bulletin, Spring 2003; Volume XIII, …
The new IRB informed MAPS today that it has decided not to accept the protocol for review. MAPS was clearly told in writing a month ago that this IRB would accept the protocol for review. Now, after we …
A new IRB has reviewed the documents from the first two IRBs that led to dead-ends and agreed to review the protocol. Documents were submitted, with feedback expected in a month or so.
Two weeks have passed without MAPS receiving an estimate for the costs of consultants from the IRC-IRB. In any case, MAPS has decided to let the review remain tabled, not to pay for consultants, and start …
